Nevertheless, the FDA recently granted an accelerated approval to atezolizumab in combination with nab-paclitaxel patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (PD-L1 IC ≥ 1% of the tumor area). Here, CD274 is linked to triple-negative breast carcinoma.